Ion channels like PIEZO2 have long fascinated scientists due to their exquisite sensitivity to mechanical forces. Embedded in the membranes of various cell types, PIEZO2 channels convert physical stimuli, such as pressure or stretch, into biological signals. These channels underlie our ability to perceive gentle breezes and even the faintest touches on the skin. However, Dr. Hammes and her team have demonstrated that PIEZO2’s functional repertoire extends into the realm of cardiovascular morphology, particularly within the developing heart’s vascular system.

Utilizing advanced mouse models genetically engineered to lack or overexpress PIEZO2 in endothelial cells, the research team meticulously charted the consequences of altered PIEZO2 activity on coronary artery development. Their findings were striking: in the absence of PIEZO2, coronary vessels often failed to mature properly, resulting in abnormally narrow or misbranched arteries. This vascular malformation compromised oxygen delivery to the heart muscle, instigating compensatory hypertrophy – a thickening of cardiac tissue primarily observable in the left ventricle. Conversely, mice harboring a hyperactive PIEZO2 variant displayed parallel defects, illuminating the finely tuned balance required for normal cardiovascular patterning.

The clinical significance of these results is underscored by the connection between PIEZO2 mutations and rare human conditions, including Marden-Walker syndrome—a genetic disorder associated with aberrant PIEZO2 function. The team’s findings suggest that mechanotransduction via PIEZO2 is indispensable for orchestrating the biomechanical signals that guide coronary vessel morphogenesis, implicating faulty PIEZO2 activity in congenital cardiovascular abnormalities. Furthermore, genome-wide association studies in humans have linked PIEZO2 variants to prevalent cardiovascular diseases such as heart failure, hypertension, and aneurysm formation, reinforcing the broader impact of this mechanosensitive channel beyond embryonic development.

Technically, the researchers employed cutting-edge tissue clearing methods combined with light sheet microscopy to visualize coronary artery formation in unprecedented detail. By staining developing vessels with specific antibodies targeting PIEZO2-expressing endothelial cells, they captured high-resolution three-dimensional images demonstrating the spatial distribution and branching patterns of coronary arteries throughout embryonic stages. This approach facilitated an in-depth analysis of how altered ion channel signaling perturbs vascular architecture, bringing to light mechanisms that were previously invisible to conventional histological techniques.

A particularly intriguing aspect of PIEZO2 revealed by the study is its temporal expression pattern. The ion channel is predominantly active during embryogenesis within the endothelial cells of coronary arteries, orchestrating vascular formation before becoming largely silent after birth. However, emerging evidence suggests that PIEZO2 may be reactivated in adult hearts under pathological conditions, such as ischemic injury or coronary artery disease. This re-expression holds exciting therapeutic potential for promoting vascular regeneration and repair, positioning PIEZO2 as a candidate target for novel cardiovascular treatments.

Building on these preclinical insights, Dr. Hammes and colleagues are now extending their work to human models. Collaborations with the Helmholtz Institute for Translational AngioCardioScience and the Max Delbrück Center’s Pluripotent Stem Cell Technology Platform enable the use of human endothelial cells derived from pluripotent stem cells. This platform allows precise manipulation and observation of PIEZO2 expression and activity in human vascular cells, potentially bridging the translational gap between murine findings and clinical applications.

This translational approach is poised to catalyze breakthroughs in diagnostic precision. By enhancing our understanding of the genetic and molecular bases of congenital heart defects via PIEZO2 pathways, early identification of at-risk individuals could become feasible. Moreover, targeting PIEZO2 function pharmacologically could provide a preventative strategy against the progression or onset of cardiovascular diseases rooted in vascular developmental anomalies.

The research also prompts a reevaluation of the role of mechanosensation in cardiovascular biology. Traditionally associated with sensory neurons and touch perception, channels like PIEZO2 are now recognized as pivotal molecular transducers integrating mechanical forces during organogenesis. These forces guide cellular behavior, vascular remodeling, and tissue homeostasis in complex and dynamic ways, underscoring the interdisciplinary nature of modern cardiovascular research.

Crucially, the study spotlights the Max Delbrück Center’s unique collaborative environment, where multidisciplinary teams converge to tackle the intricacies of disease mechanisms. Contributions from labs specializing in molecular signaling, endothelial biology, and cardiac physiology collectively facilitated a comprehensive elucidation of PIEZO2’s role. This synergy exemplifies how integrating diverse expertise accelerates discovery and fosters innovation that can directly impact patient care.

Beyond the immediate cardiovascular implications, these findings may also influence related fields such as developmental biology, regenerative medicine, and genetic disease research. Understanding how mechanical forces are sensed at the molecular level to sculpt organ systems could inform strategies to engineer tissues or modulate cell behavior in various contexts, ultimately enhancing regenerative therapies.

In conclusion, the unveiling of PIEZO2 as a mechanosensitive ion channel essential to coronary artery development marks a paradigm shift in cardiovascular biology. This pioneering research by Dr. Hammes and her team not only deepens our comprehension of the molecular mechanisms governing heart formation but also opens new frontiers for diagnostic and therapeutic innovation aimed at combating congenital and acquired heart diseases. As investigations proceed into human models and adult cardiac pathology, PIEZO2 may emerge as a fate-shaping conduit between biomechanics and medicine.

Subject of Research: Animals

Article Title: Mechanosensitive PIEZO2 channels shape coronary artery development

News Publication Date: 27-Jun-2025

Web References:

• Hammes lab: https://www.mdc-berlin.de/hammes
• Lewin lab: https://www.mdc-berlin.de/lewin
• Gerhardt lab: https://www.mdc-berlin.de/gerhardt
• Hübner lab: https://www.mdc-berlin.de/huebner
• Helmholtz Institute for Translational AngioCardioScience: https://www.mdc-berlin.de/hi-tac
• Pluripotent Stem Cell Technology Platform: https://www.mdc-berlin.de/pluripotent-stem-cells

References:
DOI: http://dx.doi.org/10.1038/s44161-025-00677-3

Image Credits:
Mireia Pampols-Perez, Max Delbrück Center

Keywords:
PIEZO2, coronary artery development, mechanosensitive ion channels, congenital heart defects, endothelial cells, mechanotransduction, cardiac hypertrophy, vascular morphogenesis, Pluripotent Stem Cells, cardiovascular regeneration

Vascular remodeling—the structural alteration of blood vessel walls—occurs in pathological contexts such as atherosclerosis, hypertension, and restenosis after angioplasty. It involves changes in cellular composition and extracellular matrix, leading to impaired vascular function. While endothelial cells lining blood vessels play a pivotal role in maintaining vascular homeostasis, their dysfunction is recognized as a key contributor to progressive vascular disease. Until now, the molecular underpinnings that regulate endothelial resilience and adaptation during remodeling remained incompletely understood.

The study spearheaded by Jiang, Bai, Hu, and colleagues centers on major vault protein, a highly conserved and abundant cytoplasmic protein initially characterized as a component of ribonucleoprotein particles called vaults. MVP’s physiological function has long been enigmatic, with previous research implicating it in multidrug resistance in cancer and intracellular transport. This latest research identifies MVP as a crucial regulator within endothelial mitochondria quality control pathways, particularly in orchestrating Parkin-mediated mitophagy.

Mitophagy serves as a specialized form of autophagy, eliminating damaged or dysfunctional mitochondria to preserve cellular bioenergetics and minimize reactive oxygen species (ROS) accumulation. Dysregulated mitochondrial turnover has been increasingly linked to endothelial dysfunction, oxidative stress, and vascular pathologies. Parkin-mediated mitophagy involves the E3 ubiquitin ligase Parkin tagging defective mitochondria, marking them for degradation via lysosomal pathways. The researchers demonstrated that MVP potentiates this process, enhancing endothelial mitochondrial turnover and thereby attenuating vascular remodeling.

Through a series of comprehensive in vitro and in vivo experiments, the authors meticulously delineated the MVP-Parkin axis’s role. Endothelial cells deficient in MVP exhibited compromised mitophagy, mitochondrial fragmentation, and elevated oxidative stress markers. Conversely, overexpression of MVP catalyzed robust mitophagic flux, preserving mitochondrial integrity under stress conditions relevant to vascular remodeling stimuli. Intriguingly, MVP was shown to physically interact with Parkin, facilitating its translocation to damaged mitochondria.

The team utilized advanced imaging techniques, including fluorescence microscopy coupled with mitophagy-specific reporters, to visualize mitochondrial dynamics and autophagosome formation in endothelial monolayers exposed to pathological stressors. In animal models, endothelial-targeted MVP knockdown exacerbated vascular remodeling following injury, with pronounced intimal hyperplasia and extracellular matrix deposition. This phenotype was significantly rescued by genetic or pharmacological enhancement of Parkin activity, confirming the functional interdependence of MVP and Parkin in endothelial cells.

At the molecular level, the data suggest that MVP serves as a scaffold or chaperone that accelerates Parkin’s recruitment and ubiquitination activity on depolarized mitochondria. This mechanistic insight clarifies previous ambiguities regarding MVP’s cellular role and elucidates how vascular endothelial cells maintain mitochondrial homeostasis during injurious stimuli. It also positions MVP as a potential biomarker and target to modulate mitophagic clearance in cardiovascular disorders.

The implications of these findings are broad and profound. Cardiovascular diseases remain the leading cause of mortality worldwide, with limited interventions addressing fundamental cellular dysfunction in vascular remodeling. By unraveling the MVP-Parkin mitophagy axis, this study paves the way for developing novel therapeutics aimed at bolstering mitochondrial quality control in endothelial cells, potentially halting or reversing pathological vessel remodeling.

Importantly, the authors propose that modulating MVP expression or mimicking its activity could be harnessed to fine-tune mitophagy without triggering detrimental autophagic overactivation, a balance that is crucial for cell survival. Moreover, MVP’s abundant expression makes it an attractive candidate for drug delivery strategies or gene therapy vectors targeting the vascular endothelium.

This work also enriches our understanding of mitochondrial dynamics in endothelial biology. Traditionally, research on endothelial dysfunction emphasized oxidative stress, inflammation, and hemodynamic forces. The revelation of a decisive mitophagy regulatory node mediated by MVP introduces an additional layer of complexity and therapeutic opportunity, underscoring mitochondria quality control as a cornerstone of vascular health.

The integration of cellular biology, molecular genetics, and cutting-edge imaging solidifies the study’s robustness and translational potential. Future research, as highlighted by the authors, should explore MVP’s regulation under diverse pathological conditions, its interactions with other mitophagy adaptors, and the feasibility of MVP-targeted interventions in clinical settings.

In sum, Jiang and colleagues have illuminated a vital cellular process intersecting mitochondrial quality control and vascular remodeling by defining the role of endothelial major vault protein in enhancing Parkin-mediated mitophagy. This discovery not only advances our molecular understanding of vascular diseases but also heralds a promising frontier for therapeutic innovation in cardiovascular medicine.

Subject of Research: The role of endothelial major vault protein in alleviating vascular remodeling through promotion of Parkin-mediated mitophagy.

Article Title: Endothelial major vault protein alleviates vascular remodeling via promoting Parkin-mediated mitophagy.

Article References:
Jiang, B., Bai, F., Hu, Y. et al. Endothelial major vault protein alleviates vascular remodeling via promoting Parkin-mediated mitophagy. Nat Commun 16, 4365 (2025). https://doi.org/10.1038/s41467-025-59644-y

Image Credits: AI Generated